Applied DNA Second Fiscal Quarter 2021 Financial Results Feature 384% Year-Over-Year Growth in Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Applied DNA Sciences (APDN) Reports In-Line Q2 EPS
May 13, 2021 4:28 PM EDTApplied DNA Sciences (NASDAQ: APDN) reported Q2 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $2.6 million.
We are pleased to deliver a strong fiscal second quarter with year-over-year revenue growth of 384%, capping an impressive first half of the fiscal year distinguished by demand for our COVID-19 diagnostics and surveillance testing offerings (cumulatively COVID-19 testing business), said Dr. James A. Hayward, president and CEO, Applied DNA. Our strategic and operational execution across non-COVID-19 testing initiatives was also notable: we launched our first-ever clinical... More
